(Q30444816)

21 June 2017

1 reference

title

Temozolomide and radiation in low-grade and anaplastic gliomas: temoradiation (English)

1 reference

21 June 2017

1 reference

David Schiff

1

1 reference

21 June 2017

publication date

18 October 2007

1 reference

21 June 2017

1 reference

21 June 2017

volume

25

1 reference

21 June 2017

issue

8

1 reference

21 June 2017

page(s)

776-784

1 reference

NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA.

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

Aberrant promoter methylation of multiple genes in oligodendrogliomas and ependymomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

Concurrent hypermethylation of multiple genes is associated with grade of oligodendroglial tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

MGMT methylation: a marker of response to temozolomide in low-grade gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

Temozolomide chemotherapy in recurrent oligodendroglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

Resectable brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

Phase II trial of temozolomide in patients with progressive low-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

Prognostic factors for survival in adult patients with cerebral low-grade glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

Acute leukemia following treatment of malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

Is protracted low-dose temozolomide feasible in glioma patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

Listeria brain abscess, Pneumocystis pneumonia and Kaposi's sarcoma after temozolomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900701509403

10.1080/07357900701509403

21 January 2018

Identifiers

DOI

1 reference

21 June 2017

1 reference